Type 2 Inflammation Biomarkers

Panelists discuss how biomarkers of type 2 inflammation, such as blood eosinophils, serum IgE, and fractional exhaled nitric oxide, can aid in diagnosing and monitoring type 2 inflammatory diseases as well as in predicting treatment response.

EP: 1.Navigating the Challenges of Respiratory Diseases

EP: 2.The Impact of Atopic Dermatitis and Prurigo Nodularis

EP: 3.Linking Type 2 Inflammation to Asthma and COPD

EP: 4.Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases

EP: 5.Type 2 Inflammation: The Link Between AD and PN

EP: 6.Personalizing Treatment Selection

EP: 7.Navigating Treatment Challenges in Chronic Skin Conditions

EP: 8.Role of Biologics in Dermatological Care

EP: 9.Biomarkers as Tools in Management of Type 2 Inflammation

EP: 10.Strategies to Manage Type 2 Inflammation in Respiratory Diseases

EP: 11.Addressing Unmet Needs and Emerging Agents

EP: 12.Future Directions for Type 2 Inflammation Management

EP: 13.Type 2 Inflammatory Diseases and Impact on Quality of Life

Now Viewing

EP: 14.Type 2 Inflammation Biomarkers

EP: 15.How Type 2 Inflammation Influences Treatment Choices

EP: 16.Complications of Uncontrolled Disease and Management of Comorbidities

EP: 17.Patient Education and Emerging Therapies

EP: 18.Unmet Needs and Future Research

• What tests or biomarkers are used to determine if a patient’s disease may be caused by type 2 inflammation? How does this information aid your medication selection process?

Related Videos

Related Content

Advertisement

July 2nd 2025

Approved Hidradenitis Suppurativa Treatments and Pipeline Show Similar Efficacy, Safety Without Head-to-Head Trials

Cameron Santoro

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 1st 2025

Sun Exposure Risks Brought to Light During UV Safety Awareness Month

Brooke McCormick

July is UV Safety Awareness Month, highlighting the growing risks of UV radiation and encouraging the use of protective measures to reduce sun-related health threats.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 30th 2025

Prolonged ED Stays, Boarding Times Among Older Adults Underscore Systemic Hospital Strain

Brooke McCormick

The recent increase in prolonged emergency department (ED) stays and boarding times for older adults reveals systemic challenges in US hospital care.

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

Related Content

Advertisement

July 2nd 2025

Approved Hidradenitis Suppurativa Treatments and Pipeline Show Similar Efficacy, Safety Without Head-to-Head Trials

Cameron Santoro

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 1st 2025

Sun Exposure Risks Brought to Light During UV Safety Awareness Month

Brooke McCormick

July is UV Safety Awareness Month, highlighting the growing risks of UV radiation and encouraging the use of protective measures to reduce sun-related health threats.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 30th 2025

Prolonged ED Stays, Boarding Times Among Older Adults Underscore Systemic Hospital Strain

Brooke McCormick

The recent increase in prolonged emergency department (ED) stays and boarding times for older adults reveals systemic challenges in US hospital care.

June 30th 2025

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

Brooke McCormick

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.